Chinese AI, chip firms are driving an onshore IPO rebound

China’s onshore tech IPO market is tracking its strongest year since 2023, with $3.1 billion raised through June 18, more than 5x the year-earlier pace. Nearly 50 companies have filed for Shanghai and Shenzhen IPOs with at least 126.1 billion yuan in planned fundraising, while CXMT is targeting a 29.5 billion yuan Shanghai listing that would be the year’s largest. Beijing and the CSRC are actively backing listings in future industries such as AI, quantum technology and semiconductors, supporting a revival in domestic tech issuance amid U.S.-China rivalry.

Analysis

The key second-order effect is not just more IPOs, but a re-routing of the AI capital stack back onshore. If mainland venues re-open as credible exit windows, domestic incumbents and state-linked suppliers gain a financing advantage over offshore/ADR peers that will increasingly have to justify capital intensity with slower foreign funding access. That should modestly compress the premium on Hong Kong-listed China AI names while improving the fundraising runway for mainland chip, equipment, and model-training ecosystems.

For BIDU, the article is mildly constructive rather than directly accretive: a mainland route for AI suppliers and model firms reduces the probability that strategic AI assets remain capital-starved or forced into subscale offshore listings. The bigger implication is competitive pressure — if domestic rivals can finance expansion more cheaply, Baidu’s relative advantage shifts from “public-market access” to execution speed and product differentiation. That is bullish only if Baidu can prove monetization faster than the ecosystem broadens.

The main risk is that this is a supply overhang story masquerading as a policy tailwind. A healthy IPO pipeline can absorb speculative demand and pull liquidity away from secondary names for weeks to months, especially in frothy tech subsegments where recent IPO pops have anchored expectations unrealistically high. If sentiment turns, these new listings may become a source of beta leakage rather than evidence of durable risk appetite.

The contrarian view is that the move is probably underappreciated for capital-market breadth but overappreciated for immediate earnings impact. Approval velocity matters more than headline support: unless regulators sustain a multi-quarter issuance cadence, the market will keep treating this as episodic policy theater. In the meantime, the best risk/reward is likely in the financial intermediaries and placement ecosystem, not in chasing the most crowded AI concept names.

Key Decisions for Investors

• Long GS / C vs short a basket of China ADRs with heavy AI optionality for 1-3 months: benefit from capital-markets activity and underwriting/financing volume while hedging direct China tech beta; risk/reward improves if mainland IPO pace stays elevated.
• Trade BIDU as a relative-value long only versus a basket of Hong Kong-listed China AI peers for 2-4 months; thesis is that domestic policy support helps strategic positioning, but the trade should be capped if offshore funding conditions improve faster than expected.
• Avoid chasing mainland AI IPO proxies after first-day pops; instead, wait for 20-30% post-listing pullbacks before long entries, as early floats can mean-revert sharply once speculative demand normalizes.
• Consider a short-duration call spread on C or GS around upcoming deal-flow data: upside comes from a sustained reopening of China tech issuance, while downside is limited if the policy push fades after a single wave of listings.
• If mainland tech issuance accelerates for another quarter, rotate out of expensive offshore China software into listed equipment and semiconductor supply-chain names; they should capture the funding impulse with less valuation risk.